Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL
Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a combination therapy regimen for DLBCL that combines chemotherapy drugs with rituximab). Polatuzumab vedotin is an antibody-drug conjugate (ADC) used to treat DLBCL, both in first-line treatment and for relapsed or refractory cases.
At the 2025 World ADC London conference, WuXi Biology presented a poster examining the potential of polatuzumab vedotin as a therapeutic agent across a panel of established, in-house, DLBCL patient-derived xenograft (PDX) models. The authors show that a single dose of polatuzumab vedotin at just 2 mg/kg could reach a comparable effect with R-CHOP. Among the 8 lymphoma PDX models tested, 50% of them were shown to be sensitive to polatuzumab vedotin treatment.
Poster_World ADC London Conference 2025_Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL
Related Content
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
VIEW RESOURCEAntibody-drug conjugates (ADCs), exemplified by HER2-targeted Enhertu and TROP2-targeted Trodelvy, have demonstrated significant therapeutic potential in cancers. However, a subset...
VIEW RESOURCE